A Decade of Reinvention There was a time when a HER2-positive breast cancer diagnosis carried a particularly difficult outlook. The biology was aggressive, treatment options were limited, and metastatic disease was often approached with the expectation of relatively short disease control. That picture has changed... Continue reading
Return to previous page
Page 2
How the Thelansis budget impact modeling framework turns a payer’s first and most literal question, “What will this cost my budget next year?” into a forecast a client can act on and a payer can independently verify. Executive Summary: Budget Impact Analysis (BIA) is the... Continue reading
Background: In 2024, a mid-size specialty pharma company approached Thelansis with a clear challenge: its hero product, a second-line therapy in a tightly contested market, was set to enter Loss of Exclusivity (LOE) in about 18 months. The drug accounted for 38% of the company’s... Continue reading
Background: A biopharmaceutical company was evaluating the investment potential of a targeted oncology asset. Initial market assessments appeared attractive. The indication had a sizable patient population, growing scientific interest, and a forecast suggesting meaningful commercial potential. However, the headline numbers raised an important concern. The... Continue reading
Advanced analytics has transformed how life sciences teams generate evidence. We can analyze massive datasets, model future markets, and simulate treatment pathways with remarkable precision. Yet despite this sophistication, many commercial and market access decisions still feel uncertain not because teams lack data, but because... Continue reading
Background: The client was advancing a Phase II biologic in a chronic inflammatory disease category already dense with competition. While early clinical data showed encouraging efficacy and a manageable safety profile, the team faced a familiar challenge: how to stand out in a market where... Continue reading
The first wave of obesity innovation proved a simple point: meaningful weight loss can be delivered at scale if patients can start therapy, stay on it, and afford it. GLP-1s turned obesity into one of the most commercially successful therapeutic categories in pharma history. By... Continue reading
Every major oncology congress has its headline moments: a trial that changes practice, a therapy that exceeds expectations, or a new mechanism that suddenly becomes the industry’s next big focus. But ESMO is rarely just about individual trial results. It is where the oncology community... Continue reading
A drug’s clinical trial data tells you how it performs under ideal conditions. It doesn’t tell you where your patients actually are, why they’re taking three years to get diagnosed, which physicians are missing them entirely, or where they’ll fall out of the funnel between... Continue reading
A therapy can post best-in-class trial data and still stall at launch. Not because the science was wrong, but because nobody could tell a payer what happens after the trial ends, when the drug meets real patients, real budgets, and real infrastructure. That gap is... Continue reading
More
More
- Report & Insights
- Strategy Products
Strategy Products
- Consulting Services
- Media
Media
